Our feline friends can suffer a heart disease that affects 1 out of 7 cats. A clinical trial may give a glimmer of hope to cats, and people too.
Researchers with the University of California (UC) conducted a clinical trial to treat HCM with a drug called MYK-461. The results are promising to both cats and humans.
Hypertrophic cardiomyopathy (HCM) thickens the heart ventricles that may have fatal consequences. Cats who have this could experience blood clots, congestive heart failure and sudden death.
For people, HCM can occur at any age. One out of 500 people have the disease. While some people can have no symptoms of the disease and can live normally, others may develop a worsening symptoms of chest pain and fatigue. In worst case, HCM can lead to death.
In the clinical trial, the scientists treated five HCM-stricken cats with MYK-461. The drug cured the obstructions in the left ventricles in all five cats.
"The positive result in these five cats shows that MYK-461 is viable for use in cats as a possible option to halt or slow the progression of HCM," said study lead Joshua Stern, chief of the cardiology service at the UC Davis veterinary hospital.
It is important to take note that only some symptoms have been eliminated in the clinical trial. The researchers are planning for a large-scale clinical trial.
"There has been little to no progress in advancing the treatment of HCM in humans or animals for many years," Stern said. "This study brings new hope for cats and people."
The researchers reported
their findings to PLOS One.
See: First 3D-Printed Blood Vessels Successfully Implanted in Monkeys Grow Into Natural Vessels!